Alivus Life Sciences [ALIVUS] vs Piramal Pharma [PPLPHARMA] Detailed Stock Comparison

Alivus Life Sciences Limited

NSE
Loading...

Piramal Pharma Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Alivus Life Sciences Limited wins in 12 metrics, Piramal Pharma Ltd. wins in 6 metrics, with 0 ties. Alivus Life Sciences Limited appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Alivus Life Sciences Limited Piramal Pharma Ltd. Better
P/E Ratio (TTM) 23.91 269.79 Alivus Life Sciences Limited
Price-to-Book Ratio 4.30 2.47 Piramal Pharma Ltd.
Debt-to-Equity Ratio 2.01 60.08 Alivus Life Sciences Limited
PEG Ratio 0.42 -0.38 Alivus Life Sciences Limited
EV/EBITDA 16.27 25.20 Alivus Life Sciences Limited
Profit Margin (TTM) 21.64% -1.84% Alivus Life Sciences Limited
Operating Margin (TTM) 31.45% -0.80% Alivus Life Sciences Limited
EBITDA Margin (TTM) 31.45% N/A N/A
Return on Equity 17.24% 1.12% Alivus Life Sciences Limited
Return on Assets (TTM) 14.24% 0.58% Alivus Life Sciences Limited
Free Cash Flow (TTM) $2.25B $2.28B Piramal Pharma Ltd.
Dividend Yield N/A 0.07% N/A
1-Year Return 1.40% -16.24% Alivus Life Sciences Limited
Price-to-Sales Ratio (TTM) 5.16 2.25 Piramal Pharma Ltd.
Enterprise Value $125.71B $240.47B Piramal Pharma Ltd.
EV/Revenue Ratio 5.00 2.71 Piramal Pharma Ltd.
Gross Profit Margin (TTM) 58.92% 63.25% Piramal Pharma Ltd.
Revenue per Share (TTM) $205 $67 Alivus Life Sciences Limited
Earnings per Share (Diluted) $44.21 $-1.23 Alivus Life Sciences Limited
Beta (Stock Volatility) 0.01 0.19 Alivus Life Sciences Limited

Alivus Life Sciences Limited vs Piramal Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

ALIVUS
PPLPHARMA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Alivus Life Sciences Limited-0.91%-3.01%-2.91%13.96%18.77%14.38%
Piramal Pharma Ltd.0.05%-4.15%4.19%9.65%-8.26%-1.69%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Alivus Life Sciences Limited1.40%-2.66%-2.66%-2.66%-2.66%-2.66%
Piramal Pharma Ltd.-16.24%115.91%3.17%3.17%3.17%3.17%

Performance & Financial Health Analysis: Alivus Life Sciences Limited vs Piramal Pharma Ltd.

MetricALIVUSPPLPHARMA
Market Information
Market Cap i₹130.29B₹199.68B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i107,3512,496,822
90 Day Avg. Volume i93,3563,143,094
Last Close₹1,038.10₹167.01
52 Week Range₹819.00 - ₹1,148.40₹132.30 - ₹220.85
% from 52W High-9.60%-24.38%
All-Time High₹1,251.00 (Feb 03, 2025)₹307.90 (Nov 04, 2024)
% from All-Time High-17.02%-45.76%
Growth Metrics
Quarterly Revenue Growth0.05%-0.03%
Quarterly Earnings Growth0.10%-0.05%
Financial Health
Profit Margin (TTM) i0.22%-0.02%
Operating Margin (TTM) i0.31%-0.01%
Return on Equity (TTM) i0.17%0.01%
Debt to Equity (MRQ) i2.0160.08
Cash & Liquidity
Book Value per Share (MRQ)₹245.82₹61.03
Cash per Share (MRQ)₹53.22₹5.63
Operating Cash Flow (TTM) i₹4.37B₹2.44B
Levered Free Cash Flow (TTM) i₹4.86B₹911.30M
Dividends
Last 12-Month Dividend Yield iN/A0.07%
Last 12-Month Dividend iN/A₹0.14

Valuation & Enterprise Metrics Analysis: Alivus Life Sciences Limited vs Piramal Pharma Ltd.

MetricALIVUS (Apr 24, 2026)PPLPHARMA (Apr 21, 2026)
Price Ratios
P/E Ratio (TTM) i23.91269.79
Forward P/E i20.8967.23
PEG Ratio i0.42-0.38
Price to Sales (TTM) i5.162.25
Price to Book (MRQ) i4.302.47
Market Capitalization
Market Capitalization i₹130.29B₹199.68B
Enterprise Value i₹125.71B₹240.47B
Enterprise Value Metrics
Enterprise to Revenue i5.002.71
Enterprise to EBITDA i16.2725.20
Risk & Other Metrics
Beta i0.010.19
Book Value per Share (MRQ) i₹245.82₹61.03

Financial Statements Comparison: Alivus Life Sciences Limited vs Piramal Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricALIVUS (2025)PPLPHARMA (2025)
Revenue/Sales i23.40B90.61B
Cost of Goods Sold i10.99B35.72B
COGS % of Revenue i47.0%39.4%
Gross Profit i12.41B54.89B
Gross Margin i53.0%60.6%
Research & Development iN/A971.30M
Operating Income (EBIT) i6.24B6.79B
Operating Margin i26.7%7.5%
EBITDA i7.11B16.89B
EBITDA Margin i30.4%18.6%
Pre-Tax Income i6.54B4.15B
Pre-Tax Income % of Revenue i28.0%4.6%
Income Tax i1.69B3.24B
Income Tax % of Revenue i7.2%3.6%
Net Income (Profit) i4.86B911.30M
Profit Margin i20.8%1.0%

Balance Sheet & Liquidity Metrics

MetricALIVUS (2025)PPLPHARMA (2025)
Cash & Equivalents i710.62M3.69B
Total Current Assets i23.35B57.97B
Total Current Assets % of Revenue i99.8%64.0%
Total Current Liabilities i4.70B37.66B
Total Current Liabilities % of Revenue i20.1%41.6%
Long-Term Debt i509.58M33.13B
Long-Term Debt % of Revenue i2.2%36.6%
Total Shareholders Equity i28.17B81.25B
Retained Earnings i17.77B10.49B
Retained Earnings % of Revenue i76.0%11.6%
Property, Plant & Equipment i671.06M250.60M

Cash Flow Statement Comparison

MetricALIVUS (2025)PPLPHARMA (2025)
Operating Cash Flow i4.37B2.44B
Operating Cash Flow % of Revenue i18.7%2.7%
Capital Expenditures i-1.66B-6.59B
Free Cash Flow i2.25B2.28B
FCF Margin i9.6%2.5%
Debt Repayment iN/A-10.65B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricALIVUSPPLPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i122.74M1.32B
Float Shares i30.82M608.76M
% Held by Insiders i76.10%54.54%
% Held by Institutions i7.86%20.41%
% Held by Public i16.04%25.05%

Dividend Analysis & Yield Comparison: Alivus Life Sciences Limited vs Piramal Pharma Ltd.

MetricALIVUSPPLPHARMA
Last 12-Month Dividend iN/A₹0.14
Last 12-Month Dividend Yield iN/A0.07%
3-Year Avg Annual Dividend iN/A₹0.08
3-Year Avg Dividend Yield iN/A0.07%
3-Year Total Dividends iN/A₹0.25
Ex-Dividend DateN/AJul 16, 2025